Acorda Therapeutics traded at $1.02 this Tuesday April 9th, decreasing $0.18 or 15.00 percent since the previous trading session. Looking back, over the last four weeks, Acorda Therapeutics lost 91.50 percent. Over the last 12 months, its price fell by 90.64 percent. Looking ahead, we forecast Acorda Therapeutics to be priced at 0.99 by the end of this quarter and at 0.90 in one year, according to Trading Economics global macro models projections and analysts expectations.
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. Its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation is used in the development of variety of inhaled medicines. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). It markets Inbrija for intermittent treatment of off episodes, also known as off periods, in people with Parkinson's disease treated with carbidopa/levodopa. Ampyra is a drug to improve walking in adults with multiple sclerosis. Its product pipelines includes ARCUS for acute migraine, Cimaglermin alfa for heart failure and rHIgM22 for multiple sclerosis.